

**IN THE UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO**

**IN RE: NATIONAL PRESCRIPTION
OPIATE LITIGATION,**

MDL No. 2804

**Master Docket No.:
1:17-MD-02804-DAP**

This document applies to:

Hon. Judge Dan A. Polster

ALL CASES

CORPORATE DISCLOSURE STATEMENT

Pursuant to the Corporate Disclosure Statement provisions in Local Civil Rule 3.13(b) and Local Criminal Rule 16.2: Any non-governmental corporate party to a proceeding must file a statement identifying all its parent, subsidiary and other affiliate corporations and listing any publicly held company that owns 10% or more of the party's stock. A party must file the statement upon filing a complaint, answer, motion, response or other pleading in this Court, whichever occurs first. The obligation to disclose any changes will be continuing throughout the pendency of the case.

In compliance with those provisions, this Corporate Disclosure Statement is filed on behalf of: Cephalon, Inc. and Teva Pharmaceuticals USA, Inc.

1. Is said party a parent, subsidiary or other affiliate of a publicly owned corporation?
 X Yes No

If the answer is Yes, list below the identity of the parent, subsidiary or other affiliate corporation and the relationship between it and the named party:

- a. Defendant Cephalon, Inc. is directly owned by Cupric Holding Co., Inc., which is directly owned by Teva Pharmaceutical Industries, Ltd. ("Teva Ltd.").
- b. Defendant Teva Pharmaceuticals USA, Inc. is directly owned by: (i) Orvet UK Unlimited (Majority Shareholder), which is directly owned by Teva Pharmaceuticals Europe B.V., which is directly owned by Teva Ltd.; and (ii) Teva Pharmaceutical Holdings Coöperatieve U.A. (Minority Shareholder), which is directly owned by IVAX LLC, a direct subsidiary of Teva USA.
- c. No publicly held corporation holds more than 10% or more of Teva Ltd.'s stock.

2. Is there a publicly owned corporation, not a party to the case, that has a financial interest in the outcome?

_____ Yes X No

If the answer is Yes, list the identity of such corporation and the nature of the financial interest:

Dated: June 1, 2018

Respectfully submitted,

/s/ Steven A. Reed

Steven A. Reed
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103
Telephone: 215.963.5000
Facsimile: 215.963.5001
steven.reed@morganlewis.com

*Counsel for Cephalon, Inc. and Teva
Pharmaceuticals USA, Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on June 1, 2018, a copy of the foregoing **Corporate Disclosure Statement** was filed electronically. Notice of this filing will be sent to all parties by operation of the Court's electronic filing system. Parties may access this filing through the Court's system.

/s/ Steven A. Reed

Steven A. Reed